<ol id="bpbtn"><address id="bpbtn"></address></ol>

<sub id="bpbtn"><thead id="bpbtn"></thead></sub>

      <p id="bpbtn"></p>

            <mark id="bpbtn"></mark>
            <delect id="bpbtn"><menuitem id="bpbtn"><b id="bpbtn"></b></menuitem></delect>
            <ruby id="bpbtn"><progress id="bpbtn"></progress></ruby>

                    About Us

                    DM Intelligence

                    DM Intelligence is an artificial intelligence development company that built AI solutions for small molecule drugs with high specific and affinity. Our proprietary platform, Artificial Intelligence Drug Discovery Platform (AI-DDP), integrates artificial intelligence technologies into the medical field to provide better service to pharmaceutical companies, academic centers and biotech companies.

                    AI-DDP allow us to optimize leads with specific desired properties as well as design small molecules targeting specific site or receptor. Our platform has extensive capabilities of analyzing and predicting physicochemical properties, biological and toxicological activities of candidate drugs based on their structures. With all these techniques, we strive for break thoughts in the future of drug discovery and research.

                    Cooperation

                    Products


                    Hit Identification

                    Discovering a new drug is more challenge and difficult. Hit identification is the first step for a successful drug discovery project. Manual screening and high-throughput screening become cumbersome and expensive, which identify one or few compounds from hundreds, thousands or even millions of compounds with the ability to inhibit the activity of targets. We develop innovative solutions to this problem: using molecular geometry model and energy model based on structural information to predict molecule-protein interactions and identify right, validated and high-quality hits.





                    Predictive Models

                    The quality of the candidate is the key determinant of a successful outcome of drug discovery programmes. Carrying out prediction studies prior to clinical development, such as analyzing and predicting physicochemical properties, biological and toxicological activities of candidate drugs may help in reducing workload, saving time, improving efficiency.




                    Founder/CEO WeiDong Xie

                    PhD. Imperial College London.

                    Professor, Sun Yat-sen University

                    Director, St. Jude Children's Research Hospital

                    CTO, CK Life Science Group

                    CEO Lindan Biotech, Canada.

                    VP Biotherapy Inc
                    Dr. RiQiang Deng

                    Professor, Sun Yat-sen University

                    Bioinformatics scientist IT, and AI, deep learning, neural network.
                    Dr. Da-Wei Gu

                    PhD. Imperial College London

                    Professor in Engineering, University of Leicester

                    Research interests include robust control, optimal control, optimization algorithms.

                    Chartered Engineer

                    a Fellow of IET
                    Dr.PingHua Sun

                    At present, he is the head of Department of pharmacy, School of pharmacy, Jinan University

                    Master of pharmaceutical chemistry, Shenyang Pharmaceutical University
                    Doctor of Biomedical Engineering, Jinan University
                    University of South Florida School of Medicine / Moffitt Cancer Institute postdoctoral

                    College of pharmacy,Jinan University:Assistant(2002-2004)
                    College of pharmacy,Jinan University:lecturer(2004-2010)
                    College of pharmacy,Jinan University:associate professor/Master Tutor(2010-2015)
                    College of pharmacy,Jinan University:professor/Doctoral supervisor(2015-Now)

                    Partners

                    client client client client client client client client

                    News

                    DM Intelligence Raises Approximately ¥10 Million CNY ($1.5M USD) in Angel Round for Advance AI + Drug Discovery

                    April 19, 2021
                    Know More


                    DM intelligence to attend 2021 AACR annual meeting


                    April 13, 2021
                    Know More


                    Win win cooperation to promote the research and development of artificial intelligence innovative drugs
                    DEC 19, 2020
                    Know More
                    More

                    Teams

                    WeiDong Xie

                    Founder/CEO

                    RiQiang Deng

                    Dr.

                    DaWei Gu

                    Dr.

                    PingHua Sun

                    Dr.

                    Contact Us

                    97精品国产品国语在线不卡,狠狠噜天天噜日日噜无码,超碰97人人做人人爱可以下载,国内精品久久久久影院蜜芽